(Reuters) – Japanese drugmaker Otsuka Holdings Co Ltd plans to buy U.S.-based Avanir Pharmaceuticals Inc for about $3.5 billion to expand its neurologic drug portfolio ahead of an expiration of a key drug patent.
Otsuka said subsidiary Otsuka Pharmaceutical Co Ltd would pay $17 per…
Japan’s Otsuka to buy Avanir for $3.5 billion ahead of patent cliff
No comments:
Post a Comment